Blood Podcast cover image

Pembrolizumab plus AVD for classical Hodgkin lymphoma, targeting the CD40/CD40-ligand axis in Waldenström Macroglobulinemia, and CXCR4-expressing CAR-cytokine induced killer cells in AML

Blood Podcast

00:00

The Safety and Tolerability of Pembrolysumab Therapy

Intervenous pembrolysmab 200 mg was given every 21 days, starting on cycle 1, day 1. Grade 3 to 4 non-hematologic adverse events were seen in 12 patients. Efficacy analysis performed on 29 responsive-aluable patients revealed an overall response rate of 100%.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app